Project Grant R03DE033059
- This federal Project Grant award of $1,024,812 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop novel treatments for diabetic foot ulcers (DFU). The award supports research conducted by Epoulosis Therapeutics Inc. to leverage single-cell RNA sequencing data and in vivo studies to repurpose the drug metrifonate for enhancing wound healing in DFU...
- The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $432,209 Project Grant under the Oral Diseases and Disorders Research (CFDA 93.121) program to the University of California, Los Angeles (UCLA) for a 2-year period starting on August 1, 2023. The funding supports research to investigate the role of the CXCL10-CXCR3 axis in the compounding effects of diabetes mellitus on periodontitis. Specifically, the research aims to further elucidate the role of CXCL10 in the...
- The federal Project Grant award of $310,438 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research program) to Htic, Inc. (UEI: XAMZMYUY9UA9) is focused on establishing proof-of-concept studies to develop a novel humanized monoclonal antibody (hCITH3-mAb) for the treatment of diabetic wounds. The project aims to formulate a topical delivery system for hCITH3-mAb and conduct in vivo studies to demonstrate...
- This $205,000 project grant from the National Institutes of Health's National Institute on Aging will fund research into the pathomechanics of diabetic foot ulcers at The University of Texas Southwestern Medical Center over a 12-month period. The research aims to identify more accurate markers and marker combinations for foot ulceration risk in patients with diabetic neuropathy and a history of prior ulcers. Using specialized equipment, the study will quantify two primary ulcer-causing...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $687,416 Project Grant under CFDA 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research) to Lynntech Inc., a small business technology development company based in College Station, Texas. The grant will support the development of a cutaneous gel to deliver a therapeutic with an intriguing mechanism of action to effectively treat diabetic foot ulcers (DFUs). The project aims to: (1) prepare,...
- This federal Project Grant award, funded by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research investigating the role of the Iroquois homeobox 1 (IRX1) gene in regulating oral tissue repair and regeneration. The $961,680 award to the University of Iowa aims to analyze the impact of IRX1 on gingival wound healing and identify its potential involvement in maintaining a progenitor cell niche in...
- This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $268,377 to The University of North Texas Health Science Center at Fort Worth (UNTHSC) to develop and evaluate a novel device for accelerating the healing of diabetic foot ulcers (DFUs) using high-frequency, low-amplitude vibration (HFLAV). The key objectives are to: 1) enhance...
- This Project Grant award, funded by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), supports the co-development of autologous oral mucosal grafts for therapeutic purposes. The $1,240,877 award to Cedars-Sinai Medical Center aims to engineer vascularized, functional oral tissue grafts that can be tailored to diverse clinical needs, leveraging advances in single cell/spatial multiomics, developmental...
- The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $421,625 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to the Texas A&M Engineering Experiment Station (Tees) to develop advanced tumor microenvironment chips (TME-chips) that incorporate functional blood and lymphatic capillary networks. The objective is to create innovative in-vitro systems that can accurately model oral squamous cell carcinoma (OSCC) tumor microenvironments,...
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is providing $1,060,675 to the University of Arizona to study the impact of the absent in melanoma 2 (AIM2) protein on intestinal stem cell differentiation during inflammation. The research aims to elucidate the molecular and cellular processes by which AIM2 regulates the development of...
EPITHELIAL STEM CELL DYSFUNCTION IN DIABETIC ORAL ULCER - PROJECT ABSTRACT DIABETES MELLITUS SIGNIFICANTLY DELAYS THE HEALING OF EPIDEMIC WOUNDS AS WELL AS ORAL WOUNDS, POSING A DIFFICULT CLINICAL CHALLENGE FOR ORAL SURGERIES SUCH AS TOOTH EXTRACTIONS AND FREE FLAPS. THE LACK OF COMPREHENSIVE KNOWLEDGE REGARDING THE EFFECTS OF DIABETES ON ORAL MUCOSAL HEALTH HINDERS THE DESIGN OF EFFECTIVE TREATMENT. OUR LONG-TERM GOAL IS TO IDENTIFY NOVEL THERAPEUTIC TARGETS TO IMPROVE DIABETIC WOUND MANAGEMENT. IN OUR PRELIMINARY STUDY, WE DISCOVERED THAT LONG-LIVED WNT-RESPONSIVE CELLS ARE STEM CELLS IN ORAL EPITHELIA. THESE CELLS RESIDE IN THE BASAL LAYER OF THE ORAL EPITHELIUM AND MAINTAIN THE TISSUE'S TURNOVER AND BARRIER FUNCTION BY PRECISELY BALANCING PROLIFERATION AND DIFFERENTIATION. IN RESPONSE TO INJURY, WNT-RESPONSIVE CELLS PRIORITIZE PROLIFERATION OVER DIFFERENTIATION, PRODUCING ABUNDANT PROGENY TO QUICKLY RE-EPITHELIALIZE THE WOUND. IN DIABETIC MICE, WE RECENTLY DISCOVERED THAT ORAL EPITHELIA EXHIBIT A DECREASED TURNOVER RATE AND REDUCED STRUCTURAL PROTEIN EXPRESSION. THE OVERALL OBJECTIVE OF THIS PROPOSAL IS TO DETERMINE HOW DIABETES AFFECTS THE QUANTITY, DISTRIBUTION, ACTIVITY, AND INJURY RESPONSE OF ORAL EPITHELIAL STEM CELLS USING BOTH IN VITRO AND IN VIVO MODELS. OUR CENTRAL HYPOTHESIS IS THAT DIABETES DISRUPTS THE MICROENVIRONMENT OF ORAL EPITHELIAL STEM CELLS, IMPAIRS STEM CELL FATE, AND THUS ADVERSELY AFFECTS EPITHELIAL BARRIER FUNCTION AND WOUND HEALING. TWO INDEPENDENT BUT INTERCONNECTED AIMS ARE PROPOSED. IN AIM 1, WE WILL DETERMINE THE ALTERATIONS THAT OCCUR IN ORAL EPITHELIAL STEM CELLS AND THEIR NICHE UNDER DIABETIC CONDITIONS. BASED ON OUR PRELIMINARY DATA, WE HYPOTHESIZE THAT DIABETES NEGATIVELY IMPACTS ORAL EPITHELIAL STEM CELLS AND THEIR NICHE, LEADING TO SLOWED TISSUE TURNOVER AND COMPROMISED BARRIER FUNCTION. A NOVEL LINEAGE-TRACING STRAIN WILL BE USED TO EXAMINE THE QUANTITY AND ACTIVITY OF WNT-RESPONSIVE CELLS IN AN ADULT-ONSET TYPE 2 DIABETES MODEL, WHICH CLOSELY RESEMBLES PATIENT METABOLIC CHARACTERISTICS. NICHE SIGNALING WILL BE INTERROGATED BY AN IN VITRO 3D COCULTURE MODEL. IN AIM 2, WE WILL DEFINE THE KEY MECHANISMS RESPONSIBLE FOR DELAYED DIABETIC WOUND HEALING. WE HYPOTHESIZE THAT THE INEFFECTIVE RESPONSE OF EPITHELIAL STEM CELLS TO INJURY IS THE PRIMARY CAUSE OF THE COMPROMISED HEALING OF DIABETIC WOUNDS. WE WILL CHALLENGE CONTROL AND DIABETIC MICE WITH A TRAUMATIC ORAL ULCER MODEL AND MONITOR THE HEALING PROCESS, FOCUSING ON STEM CELL ACTIVATION, PROLIFERATION, MIGRATION, AND DIFFERENTIATION. RESULTS FROM THIS PROPOSAL WILL DEMONSTRATE FOR THE FIRST TIME THE EXTENT TO WHICH DIABETES ALTERS EPITHELIAL STEM CELLS IN HOMEOSTASIS AND WOUND HEALING. THESE RESULTS ARE EXPECTED TO HAVE POSITIVE IMPACTS, AS A COMPREHENSIVE UNDERSTANDING OF THE COMPROMISED STATE OF EPITHELIAL STEM CELLS UNDER DIABETIC CONDITIONS WILL FACILITATE THE DEVELOPMENT OF EFFECTIVE THERAPIES TO ENHANCE WOUND MANAGEMENT.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $158.5k | 7/29/25 | ||
| Not listed | $158.5k | 7/30/24 |